These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26864592)

  • 41. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
    Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.
    Scalvenzi M; Villani A; Costa C; Cappello M
    Dermatol Ther; 2019 Jul; 32(4):e12971. PubMed ID: 31124200
    [No Abstract]   [Full Text] [Related]  

  • 43. Medulloblastoma: need for targeted treatment.
    Luttjeboer M; Kaspers GJ
    Expert Rev Anticancer Ther; 2006 May; 6(5):649-52. PubMed ID: 16759156
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
    Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A functional genomics approach to identify pathways of drug resistance in medulloblastoma.
    Bertrand KC; Faria CC; Skowron P; Luck A; Garzia L; Wu X; Agnihotri S; Smith CA; Taylor MD; Mack SC; Rutka JT
    Acta Neuropathol Commun; 2018 Dec; 6(1):146. PubMed ID: 30591080
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
    Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
    Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
    Routt E; Ratner D
    Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
    [No Abstract]   [Full Text] [Related]  

  • 48. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 49. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medulloblastoma--challenges in radiation therapy and the addition of chemotherapy.
    Kun LE
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):261-3. PubMed ID: 10661329
    [No Abstract]   [Full Text] [Related]  

  • 51. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 52. Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
    Ash MM; Jolly PS
    Int J Dermatol; 2015 Mar; 54(3):370-4. PubMed ID: 25039741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repurposing mebendazole for the treatment of medulloblastoma.
    Bodhinayake I; Symons M; Boockvar JA
    Neurosurgery; 2015 Feb; 76(2):N15-6. PubMed ID: 25594199
    [No Abstract]   [Full Text] [Related]  

  • 54. "Ghosts in my body": Seizure-like presentation of hypocalcemic tetany secondary to hypomagnesemia in a patient receiving cetuximab therapy for metastatic medulloblastoma.
    Kidwell KS; Kopp WE; Albano EA; Brown AE
    J Pediatr Hematol Oncol; 2014 May; 36(4):305-7. PubMed ID: 23426003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
    Juhasz ML; Marmur ES
    J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.
    Friedman HS; Mahaley MS; Schold SC; Vick NA; Falletta JM; Bullard DE; D'Souza BJ; Khandekar JD; Lew S; Oakes WJ
    Neurosurgery; 1986 Mar; 18(3):335-40. PubMed ID: 3703192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hearing loss in pediatric cancer survivors treated with cisplatin.
    Knight K
    Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):35-7. PubMed ID: 19856560
    [No Abstract]   [Full Text] [Related]  

  • 58. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
    Kaye SB; Fehrenbacher L; Holloway R; Amit A; Karlan B; Slomovitz B; Sabbatini P; Fu L; Yauch RL; Chang I; Reddy JC
    Clin Cancer Res; 2012 Dec; 18(23):6509-18. PubMed ID: 23032746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Letter: CCNU in teatment of recurrent medulloblastoma.
    Ward HW
    Br Med J; 1974 Mar; 1(5908):642. PubMed ID: 4206861
    [No Abstract]   [Full Text] [Related]  

  • 60. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management.
    Le Moigne M; Saint-Jean M; Jirka A; Quéreux G; Peuvrel L; Brocard A; Gaultier A; Khammari A; Darmaun D; Dréno B
    Support Care Cancer; 2016 Apr; 24(4):1689-95. PubMed ID: 26416491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.